亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Thawing “cold” tumors: The NRF2–COX2–PGE2 axis as a pathway to precision immunotherapy in HCC

作者
Hayato Nakagawa
出处
期刊:Hepatology [Lippincott Williams & Wilkins]
标识
DOI:10.1097/hep.0000000000001703
摘要

The introduction of immune checkpoint inhibitors (ICIs) has fundamentally reshaped the treatment paradigm for advanced hepatocellular carcinoma (HCC). In particular, the combination of programmed death-ligand 1 (PD-L1) blockade with anti–vascular endothelial growth factor (VEGF) therapy—atezolizumab plus bevacizumab (Atez/Bev)—has established a new first-line standard of care.1 Nevertheless, a substantial proportion of patients exhibit primary resistance, and many initial responders eventually develop acquired resistance, underscoring the urgent need to clarify the biological basis of immunotherapy failure in HCC and to develop biomarkers for mechanism-based patient stratification. These challenges are increasingly relevant in the context of a shifting etiological landscape. Non-viral HCC is rapidly rising worldwide, with metabolic dysfunction–associated steatotic liver disease (MASLD) emerging as a major underlying cause. Recent studies suggest that HCC arising in MASLD may be less responsive to immunotherapy,2 highlighting the importance of elucidating etiology-linked pathways that shape the tumor immune microenvironment for the development of precision immunotherapy strategies in HCC. In this issue of Hepatology, Yamamoto et al.3 address these unmet needs through an elegant, integrative approach combining mouse models, single-cell and spatial transcriptomics, and large clinical cohorts. To investigate mechanisms of resistance to combined immune-oncology (IO)–based PD-L1 blockade and VEGF inhibition (IO–VEGF therapy), the authors employed a genetically heterogeneous immunocompetent mouse model of HCC that generates multiple tumor lesions with distinct molecular features within the same host. Using this system, IO–VEGF therapy preferentially eliminated tumors with high cytotoxic T-cell infiltration and immune-activated transcriptional profiles (immune-hot), whereas lesions with limited immune infiltration persisted and expanded (immune-cold). Importantly, this shift reflected selective outgrowth of immune-evasive lesions rather than phenotypic conversion, providing a biological framework for primary resistance in HCC. Within this context, the authors identified activation of the NRF2 pathway as a defining feature of immune-evasive tumor clones. NRF2 is a master regulator of cellular stress responses,4 and activating alterations in the NRF2 pathway—including mutations in NFE2L2 or its negative regulator KEAP1—have been reported in a subset of HCCs.5 Complementary experimental analyses further supported a role for NRF2 activation in enforcing immune exclusion and resistance to IO–VEGF therapy, thereby positioning NRF2 not merely as a metabolic stress sensor, but as a determinant of tumor-intrinsic immune evasion and primary resistance to immunotherapy in HCC. Consistent with the murine findings, analysis of human cohorts revealed that tumors with high NRF2 activity exhibited immune-cold phenotypes and poor clinical responses to Atez/Bev treatment. Importantly, NRF2 activation was not restricted to tumors harboring NFE2L2 or KEAP1 mutations, but was frequently linked to accumulation of p62/SQSTM1, which stabilizes NRF2 through KEAP1 sequestration. Prior studies demonstrated that metabolic stress in MASLD promotes p62 accumulation and hepatocarcinogenesis by rewiring stress-response pathways.6,7 Building on this framework, the present study shows that the p62–NRF2 axis is enriched in non-viral HCC, particularly in MASLD-associated tumors, linking metabolic stress to tumor-intrinsic immune evasion and reduced immunotherapy responsiveness. These findings suggest that etiology-associated differences in immunotherapy efficacy may reflect activation of specific stress-response pathways rather than etiology itself. Notably, these data also indicate that NRF2-driven stress-response programs are dynamic rather than static. Analysis of paired pre-treatment and post-treatment human tumor biopsies revealed reinforcement of NRF2-associated signatures during therapy, implicating this pathway not only in primary resistance but also in the development of acquired resistance. Mechanistically, the authors show that NRF2 promotes immune exclusion through transcriptional activation of the cyclooxygenase-2 (COX2)–prostaglandin E2 (PGE2) pathway. NRF2 activation induces COX2 expression via ATF1/ATF2-dependent transcriptional programs, leading to increased intratumoral PGE2 production. This program was observed in murine models and recapitulated in human HCC cohorts, in which high NRF2 activity was associated with elevated COX2/PGE2 signatures, immune-cold tumor microenvironments, and poor responses to Atez/Bev therapy. PGE2 has emerged as a critical immunomodulatory lipid mediator in cancer. While historically linked to dendritic cell regulation and myeloid-driven immunosuppression, 2 independent studies published in 2024 demonstrated that PGE2 directly constrains antitumor immunity by limiting the expansion and effector differentiation of tumor-infiltrating stem-like CD8+ T cells through disruption of IL-2 signaling and mitochondrial fitness.8,9 In line with these findings, NRF2-high tumors displayed enhanced COX2–PGE2 signaling accompanied by marked exclusion of functional CD8+ T cells, establishing this pathway as a mechanistic link between tumor-intrinsic stress responses and immune escape in HCC. These mechanistic insights have direct therapeutic implications. In preclinical models, pharmacologic COX2 inhibition attenuated PGE2 signaling and remodeled the tumor immune microenvironment toward immune-hot states, restoring sensitivity to IO–VEGF therapy. Retrospective human analyses further showed improved outcomes in patients receiving concomitant COX2 inhibitors, such as celecoxib, during IO–VEGF treatment. Moreover, elevated circulating PGE2 levels were associated with inferior responses and shorter overall survival, supporting serum PGE2, together with NRF2-related and COX2-related transcriptional signatures, as candidate biomarkers for identifying patients with immune-cold tumors unlikely to benefit from IO–VEGF therapy alone. Collectively, these findings support a precision immunotherapy framework in HCC, guided by tumor-intrinsic stress-response programs rather than clinical stage or etiology alone (Figure 1).FIGURE 1: The NRF2–COX2–PGE2 axis as a molecular driver of immune exclusion and a therapeutic target in HCC. In NRF2-activated HCC (left), driven by genetic alterations or metabolic stress such as MASLD-mediated p62 accumulation, activation of the NRF2–COX2–PGE2 pathway promotes an immune-cold tumor microenvironment. Elevated PGE2 levels exert potent immunosuppressive effects, limiting effective antitumor immunity and conferring resistance to IO–VEGF therapy (eg, atezolizumab plus bevacizumab). Circulating PGE2 may serve as a non-invasive, blood-based biomarker indicative of this immune-resistant state. Conversely (right), pharmacological inhibition of COX2 disrupts this suppressive axis, converting the tumor microenvironment from immune-cold to immune-hot. This transition sensitizes tumors to IO–VEGF therapy and provides a conceptual framework for precision immunotherapy in HCC. Figure created with BioRender.com. Abbreviations: COX2, cyclooxygenase-2; IO–VEGF, immune-oncology (IO)–vascular endothelial growth factor (VEGF); MASLD, metabolic dysfunction–associated steatotic liver disease; PGE2, prostaglandin E2.Several considerations remain when interpreting these findings. Because COX2 is a well-established regulator of angiogenesis, the NRF2–COX2–PGE2 axis identified here may be particularly relevant in the setting of combined immune checkpoint blockade and VEGF inhibition, potentially explaining its strong association with resistance to IO–VEGF therapy. Whether this pathway similarly influences resistance to other immunotherapeutic platforms, such as CTLA-4–based IO–IO regimens, remains an important question for future studies. In addition, the biomarker potential of circulating PGE2, as well as the efficacy and safety of COX2 inhibition in immunotherapy settings, will need to be clarified in prospective studies. Finally, how NRF2–COX2–PGE2 signaling is activated or reinforced during the emergence of acquired resistance warrants further investigation. Nonetheless, this work represents a clear conceptual advance by linking tumor-intrinsic stress-response programs to immune exclusion and therapeutic resistance in HCC. Importantly, precision immunotherapy should be dynamic rather than static, as stress-response pathways such as the NRF2–COX2–PGE2 axis can be reinforced during treatment, highlighting circulating PGE2 as a potential real-time biomarker of the evolving tumor immune microenvironment. Moreover, in light of recent evidence implicating COX2–PGE2 signaling in fibrogenesis in MASLD,10 the present study extends the relevance of this pathway beyond immunotherapy resistance to the formation of a tumor-promoting niche across multiple stages of hepatocarcinogenesis. In this broader context, targeting the NRF2–COX2–PGE2 axis—including through COX2 inhibition—may offer a therapeutically attractive strategy, particularly given that COX2 inhibitors are already widely used in clinical practice, enabling the potential for drug repositioning. In summary, this study identifies the NRF2–COX2–PGE2 axis as a key tumor-intrinsic mechanism underlying immune exclusion and resistance to immunotherapy in HCC. By linking cellular stress responses to immune-cold tumor states, the work provides a mechanistic basis for treatment resistance and points toward rational combination strategies to improve immunotherapy outcomes in HCC.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LHY完成签到,获得积分10
2秒前
6秒前
香蕉乐曲完成签到,获得积分10
25秒前
49秒前
null的应助被科研通管家采纳,获得10
1分钟前
沉静的愫完成签到,获得积分10
1分钟前
1分钟前
ww完成签到,获得积分10
1分钟前
ww发布了新的文献求助10
1分钟前
1分钟前
adgn发布了新的文献求助10
1分钟前
老实的石头完成签到,获得积分10
2分钟前
2分钟前
个性鹭洋完成签到,获得积分10
2分钟前
丘比特的应助被adgn采纳,获得10
2分钟前
2分钟前
戴肉肉完成签到 ,获得积分10
2分钟前
深情安青的应助被科研通管家采纳,获得10
2分钟前
专注湘完成签到,获得积分10
3分钟前
范特西完成签到 ,获得积分10
3分钟前
忍冬完成签到,获得积分10
3分钟前
就吃一小口完成签到 ,获得积分10
3分钟前
AlexMoradi452发布了新的文献求助50
3分钟前
友好怜菡完成签到,获得积分10
4分钟前
跳跃的咖啡豆完成签到,获得积分10
4分钟前
4分钟前
4分钟前
盐水菠萝完成签到,获得积分10
4分钟前
rubbish发布了新的文献求助10
4分钟前
Wei发布了新的文献求助10
4分钟前
盐水菠萝发布了新的文献求助10
4分钟前
深情安青的应助被林楚棋采纳,获得10
4分钟前
陈淋完成签到,获得积分10
4分钟前
小巧的孤丹完成签到,获得积分10
4分钟前
null的应助被科研通管家采纳,获得10
4分钟前
大模型的应助被科研通管家采纳,获得10
4分钟前
4分钟前
所所的应助被科研通管家采纳,获得10
4分钟前
4分钟前
null的应助被科研通管家采纳,获得10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173069
求助须知:如何正确求助?哪些是违规求助? 9565519
关于积分的说明 21780335
捐赠科研通 7765068
什么是DOI,文献DOI怎么找? 3431528
关于科研通互助平台的介绍 2555609
邀请新用户注册赠送积分活动 2476668